Anti-endotoxin capacity and reticulo-endothelial function in alcohol-related liver cirrhosis: A randomized pilot study comparing a probiotic preparation versus lactulose

International Medical Journal

Volumn 8, Issue 2, 2001, Pages 101-107

  Barreto Zuniga, R ^a   Naito, Y ^a   Li, Z I ^a   Zhang, D ^a   Yoshioka, M ^a   Ideo, G M ^a   Gelosa, F ^a   Mondazzi, L ^a   Bobadilla, J ^a   Marotta, F ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Endotoxin; Lactulose; Macrophage colony stimulating factor; Oxidative burst ability; Probiotic

Indexed keywords

ALBUMIN; COLONY STIMULATING FACTOR 1; ENDOTOXIN; HIGH DENSITY LIPOPROTEIN; LACTULOSE; PROBIOTIC AGENT; ZYMOSAN;

ADULT; AGED; ALCOHOL ABUSE; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BLOOD CHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; FEMALE; HUMAN; MALE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY BURST; RETICULOENDOTHELIAL SYSTEM;

EID: 0034942332     PISSN: 13412051     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis
2. Role of serum complement, immunoglobulins and cell-mediated immune system in the pathogenesis of spontaneous bacterial peritonitis
3. Portal venous and systemic endotoxinemia in patients without liver disease and systemic endotoxinemia in patients with cirrhosis
4. Endotoxins and pathogenesis of hepatic and gastrointestinal diseases
5. Endotoxinemia in a series of 104 patients with chronic liver disease: Prevalence and significance
6. Detection of endotoxin in plasma and ascitic fluid of patients with cirrhosis: Its clinical significance
7. Endotoxin levels measured by a chromogenic assay in portal and peripheral venous blood in patients with cirrhosis
8. Endotoxinemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess
9. Bacterial microflora in the jejunum of chronic alcoholics
10. The leaky gut of alcoholism: Possible route of entry for toxic compounds
11. Modulation of F-met-leu-phe induced chemotactic activity and superoxide production by neutrophils during chronic ethanol ingestion
12. Enhanced tumor necrosis factor and interleukin-1 in an experimental model of massive liver cell necrosis/fatal hepatitis in mice
13. Enhanced tumor necrosis factor and interleukin-1 in fulminant hepatic failure
14. Lactitol versus lactulose in the treatment of acute portal-systemic encephalopathy - A controlled trial
15. Lactitol and lactulose for treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomized, cross-over study
16. Lactitol in the treatment of chronic hepatic encephalopathy. A randomized cross-over comparison with lactulose
17. Treatment of hepatic encephalopathy by alterations of intestinal flora with Lactobacillus acidophilus
18. Lactobacillus acidophilus (Enpac) in treatment of hepatic encephalopathy
19. Longterm effects of Enterococcus faeccum SF6g versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy
20. Gut flora manipulation mitigates ethanol-induced liver damage and endotoxinemia: Experimental comparison between a novel probiotic and metronidazole
21. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: Reevaluation with an improved chromogenic assay
22. "Hidden" endotoxin in plasma of patients with alcoholic liver disease
23. Chromogenic endotoxin assay in plasma selection of plasma pretreatment and production of standard curves
24. Endotoxin inactivating of plasma in patients with liver cirrhosis
25. Quantitation and identification of human monocyte colony-stimulating factor in human serum by enzyme-linked immunosorbent assay
26. Detection of endogenous macrophage colony-stimulating factor (M-CSF) in human blood
27. Macrophage colony stimulating factor and hepatitis
28. 2 production in phagocytizing macrophages
29. Use of 2-methyl-6-phenyl-3,7-dihydroimidazol(1,2-a)pyrazin-3-one for assay of superoxide anions in phagocytizing granulocytes
30. Increased superoxide anion production by immunologically activated and chemically elicited macrophages
31. Uptake by liver cells of endotoxin following its intravenous injection
32. Endotoxin, reticuloendothelial function and liver injury
33. Endotoxinemia in patients with chronic liver diseases: Relationship to severity of liver disease, presence of esophageal varices and hyperdynamic circulation
34. Endotoxin spillover in viral hepatitis
35. Endotoxin inactivation in plasma from septic patients: An in vitro study
36. An experimental study on the severe type of alcoholic liver disease: A pathogenetic role of potentiated activation of complement system by endotoxin after chronic ethanol consumption
37. Effects of polysaccharide chain of lipopolisaccharide in an experimental massive
38. The importance of intestinal endotoxins in liver disease
39. Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease
40. Interleukin-6 production by peripheral blood monocytes in patients with chronic liver disease and acute viral hepatitis
41. High interleukin-6 serum levels and increased production by leukocytes in alcoholic liver cirrhosis: Correlation with IgA serum levels and lymphokines production
42. The role of cytokines in the pathophysiology of chronic liver disease
43. Serum levels of macrophage colony stimulating factor in liver disease
44. Induction of monocyte migration by recombinant macrophage colony-stimulating factor
45. The effect of prednisolone and interferons on serum macrophage colony stimulating factor concentrations in chronic hepatitis B
46. Hepatic damage induced by transcatheter arterial chemoembolization elevates serum concentrations of macrophage-colony stimulating factor
47. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection
48. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis
49. Decreased superoxide-generating activity of blood monocytes from patients with hepatic cirrhosis
50. Impaired ability of neutrophils to produce oxygen-derived free radicals in patients with chronic liver disease and hepatocellular carcinoma
51. Effect of an enriched probiotic preparation on interferon production decline with aging process: An experimental study
52. Enhancement of host resistance to microbial infection in dietary fat-related immunodysfunction: Effect of an enriched probiotic preparation